D
David T. Bollag
Researcher at Hoffmann-La Roche
Publications - 10
Citations - 1387
David T. Bollag is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Bevacizumab & Carboplatin. The author has an hindex of 6, co-authored 10 publications receiving 1141 citations.
Papers
More filters
Journal ArticleDOI
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
Eric Pujade-Lauraine,Felix Hilpert,Béatrice Weber,Alexander Reuss,Andreas Poveda,Gunnar B. Kristensen,Roberto Sorio,Ignace Vergote,Petronella O. Witteveen,Aristotelis Bamias,Deolinda Pereira,Pauline Wimberger,Ana Oaknin,Mansoor Raza Mirza,Philippe Follana,David T. Bollag,Isabelle Ray-Coquard +16 more
TL;DR: Adding bevacizumab to chemotherapy statistically significantly improved PFS and ORR; the OS trend was not significant.
Journal ArticleDOI
AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC).
Eric Pujade-Lauraine,Felix Hilpert,Béatrice Weber,Alexander Reuss,Andres Poveda,Gunnar B. Kristensen,Roberto Sorio,Ignace Vergote,Petronella O. Witteveen,Aristotelis Bamias,Deolinda Pereira,Pauline Wimberger,Ana Oaknin,Mansoor Raza Mirza,Philippe Follana,David T. Bollag,Isabelle Ray-Coquard,Aurelia Investigators +17 more
TL;DR: AURELIA is the first randomized trial of BEV in PT-resistant OC and significantly improved progression-free survival vs CT alone, and provided objective response rate (ORR), overall survival, safety, and quality of life.
Journal ArticleDOI
Safety of bevacizumab in metastatic breast cancer patients undergoing surgery
Javier Cortes,Mireia Caralt,Suzette Delaloge,Hernán Cortés-Funes,Jean-Yves Pierga,Kathleen I. Pritchard,David T. Bollag,David Miles +7 more
TL;DR: Surgery can be performed on patients with mBC undergoing bevacizumab therapy with a low risk of severe bleeding or wound-healing complications post surgery, if current labelling recommendations are adhered to.
Journal ArticleDOI
Weekly Paclitaxel (PAC), Pegylated Liposomal Doxorubicin (PLD) or Topotecan (TOP) ± Bevacizumab (BEV) in Platinum (PT)-Resistant Recurrent Ovarian Cancer (OC): Analysis by Chemotherapy (CT) Cohort in the GCIG Aurelia Randomised Phase III Trial
Andres Poveda,Frédéric Selle,Felix Hilpert,Alexander Reuss,A. Pasic,Antonella Savarese,Ignace Vergote,Petronella O. Witteveen,Aristotle Bamias,David T. Bollag,Eric Pujade-Lauraine +10 more
TL;DR: In PT-resistant OC, the improvement in PFS and ORR gained by adding BEV to single-agent CT was observed across all CT cohorts, and increased CT exposure associated with prolonged PFS accounts for some increase in cumulative CT toxicity.
Journal ArticleDOI
Safety of front-line bevacizumab (BEV) combined with weekly paclitaxel (wPAC) and q3w carboplatin (C) for ovarian cancer (OC): Results from OCTAVIA.
Antonio González-Martín,Laurence Gladieff,Bengt Tholander,Daniel Stroyakovsky,Martin Gore,J. G. M. Segalla,An K.L. Reyners,Nadezhda V. Kovalenko,Ana Oaknin,Frédéric Selle,David T. Bollag,Sandro Pignata,Octavia Investigators +12 more
TL;DR: This data indicates that front-line BEV + q3w PAC + Q3w C followed by BEV alone significantly improved progression-free survival (PFS) vs chemo...